Browsing by Author "Leander, M."
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- Chemokine Receptor Expression on Normal Blood CD56(+) NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell PopulationPublication . Lima, M.; Leander, M.; Santos, M.; Santos, A.; Lau, C.; Queirós, M.; Gonçalves, M.; Fonseca, S.; Moura, J.; Teixeira, M.; Orfao, A.Studies of chemokine receptors (CKR) in natural killer- (NK-) cells have already been published, but only a few gave detailed information on its differential expression on blood NK-cell subsets. We report on the expression of the inflammatory and homeostatic CKR on normal blood CD56(+low) CD16(+) and CD56(+high) CD16(-/+low) NK-cells. Conventional CD56(+low) and CD56(+high) NK-cells present in the normal PB do express CKR for inflammatory cytokines, although with different patterns CD56(+low) NK-cells are mainly CXCR1/CXCR2(+) and CXCR3/CCR5(-/+), whereas mostly CD56(+high) NK-cells are CXCR1/CXCR2(-) and CXCR3/CCR5(+). Both NK-cell subsets have variable CXCR4 expression and are CCR4(-) and CCR6(-). The CKR repertoire of the CD56(+low) NK-cells approaches to that of neutrophils, whereas the CKR repertoire of the CD56(+high) NK-cells mimics that of Th1(+) T cells, suggesting that these cells are prepared to migrate into inflamed tissues at different phases of the immune response. In addition, we describe a subpopulation of NK-cells with intermediate levels of CD56 expression, which we named CD56(+int) NK-cells. These NK-cells are CXCR3/CCR5(+), they have intermediate levels of expression of CD16, CD62L, CD94, and CD122, and they are CD57(-) and CD158a(-). In view of their phenotypic features, we hypothesize that they correspond to a transitional stage, between the well-known CD56(+high) and CD56(+low) NK-cells populations.
- Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasmsPublication . Torres, C.; Fonseca, A.; Leander, M.; Matos, R.; Morais, S.; Campos, M.; Lima, M.Background Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to be established. Objectives To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers and to investigate whether they correlate with other clinical and laboratory data. Patients and Methods Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory data were obtained from hospital records. Results We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients, while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between the CD142+ CEC counts and the number of thrombotic events. Conclusions Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC may express different activation-related phenotypes depending on the disease status.
- CONTRIBUTO DA CITOMETRIA DE FLUXO PARA O ESTUDO DOS RETICULÓCITOSPublication . Queirós, M.; Moreira, S.; Leander, M.; Freitas, I.; Cleto, E.; Santos, F.; Henriques, M.; Teixeira, F.; Iglésias, I.; Santos, A.; Santos, M.; Gonçalves, M.; Fonseca, S.; Lau, C.; Bini-Antunes, M.; Teixeira, M.; Pinho, L.; Santos-Silva, A.; Lima, M.Os reticulócitos são eritrócitos jovens cuja presença no sangue periférico (SP) reflecte a actividade eritropoiética da medula óssea. Assim e apesar de, em determinadas situações de stress ou em diversas patologias hematológicas, se poderem encontrar no SP reticulócitos em diferentes estadios de maturação,pouco se sabe acerca deles. Este trabalho teve como objectivo caracterizar fenotipicamente as várias fases de maturação dos reticulócitos por citometria de fluxo (CF).
- Expressão dos recetores de quimiocinas, CXCR3 e CCR5, nas células natural killer do sangue de cordão umbilicalPublication . Bini-Antunes, M.; Leander, M.; Rebelo, R.; Benevides, P.; Santos, A.; Rodrigues, J.; Oliveira, L.; Queirós, M.; Santos, M.; Gonçalves, M.; Fonseca, S.; Lau, C.; Teixeira, M.; Lima, M.
- MATURAÇÃO DA LINHA ERITRÓIDE NA MEDULA ÓSSEA POR CITOMETRIA DE FLUXOPublication . Queirós, M. L.; Cerejo, L.; Leander, M.; Freitas, I.; Cleto, E.; Barbot, J.; Gonçalves, M.; Santos, M.; Santos, A.; Fonseca, S.; Lau, C.; Teixeira, M. A.; Pinho, L.; Santos-Silva, A.; Lima, M.MATURAÇÃO DA LINHA ERITRÓIDE NA MEDULA ÓSSEA POR CITOMETRIA DE FLUXO Maria Luís Queirós1,2,3, Liliana Cerejo1,4, Magdalena Leander1,3, Inês Freitas3,5, Esmeralda Cleto3,6, José Barbot3,7, Marta Gonçalves1,3, Marlene Santos1,3, Ana Helena Santos1,3,8, Sónia Fonseca1,3, Catarina Lau1,3, Maria Anjos Teixeira1,3, Luciana Pinho1,3, Alice Santos-Silva2, Margarida Lima1,3,8 1Serviço Hematologia Clínica, Laboratório de Citometria, HSA/CHP; 2Serviço de Bioquímica, FF/UP; 3UMIB/ICBAS/UP; 4Mestrado em Análises Clínicas e Saude Pública, ICS/UCP; 5Serviço de Hematologia Laboratorial, HSA/CHP; 6Serviço de Pediatria, HMP/CHP e HSA/CHP; 7Unidade de Hematologia Pediátrica, HMP/CHP; 8Consórcio Euroflow. Hospital de Santo António, Centro Hospitalar do Porto (HSA/CHP), Porto. Faculdade de Farmácia, Universidade do Porto (FF/UP), Porto. Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), Porto. Instituto de Ciências da Saúde, Universidade Católica Portuguesa (ICS/UP), Porto. Hospital Maria Pia, Centro Hospitalar do Porto (HSA/CHP), Porto. Consórcio Euroflow. Introdução No processo de maturação dos eritrócitos do sangue (RBC), as células eritróides (ERI) sofrem uma série de mudanças dentro da medula óssea (MO), correspondentes a fases de maturação específicas que são identificadas por microscopia de luz, usando critérios morfológicos e citoquímicos. No entanto, pouco se sabe sobre as alterações imunofenotipicas que caracterizam a maturação ERI normal. Objectivo Caracterizar fenotipicamente as várias fases de maturação da linha eritróide por citometria de fluxo (CF). Material e Métodos Foram estudados por CF 15 aspirados de medula óssea de indivíduos adultos sem doença hematológica. O estudo foi efectuado utilizando o tubo de 8 cores recomendado pelo consórcio Euroflow para o estudo das ERI nas síndromes mielodisplásicos (SMD): anti-CD45 (PO) / anti-HLA-DR (PB) / anti-CD71 (APC-H7) / anti-CD33 (APC) /anti-CD117 (PC7) / anti-CD34 (PERCP Cy5.5) / anti-CD105 (PE) / anti-CD36 (FITC). As amostras foram adquiridas no citómetro NaviosTM (Becman Coulter) e analisadas com o software Infinicyt (Cytognos). Resultados Utilizando este protocolo identificamos 4 estadios imunofenotípicos, um correspondendo às ERI mais imaturas (estadio 1: CD71+CD36+CD105+CD117+CD34+; média de 0.9%; variando de 0.1 a 1.7%) e três estadios subsequentes caracterizados pela perda sequencial de CD34 (estadio 2: CD71+CD36+CD105+CD117+CD34-; 5.6%, 3.4 a 7.6%), CD117 (estadio 3: CD71+CD36+CD105+CD117-CD34-; 32.2%; 15.6 a 49.8%) e CD105 (estadio 4: CD71+CD36+CD105-CD117-CD34-; 61.3%, 41.1 a 78.2%) Discussão O tubo recomendado pelo Euroflow para o estudo das ERI nos SMD permitiu identificar 4 estadios de diferenciação dos RBC, os quais correspondem provavelmente aos quatro estadios que são identificados convencionalmente por critérios morfológicos: estadios 1 - pró-eritroblastos; estadio 2 - eritroblastos basófilos; estadio 3 - eritroblastos policromáticos; e estadio 4 - eritroblastos ortocromáticos. É necessário efectuar mais estudos para caracterizar melhor estas populações, para as comparar com as obtidas por critérios morfológicos e para as utilizar para identificar e monitorizar alterações nas ERI em várias doenças hematológicas primárias e secundárias. Apresentador: Maria Luís Queirós, Técnica Superior de Saúde, Serviço Hematologia Clínica, Laboratório de Citometria, HSA/CHP; Aluna de Doutoramento em Ciências Farmacêuticas, FF/UP.
- Metabolic control of T cell immune response through glycans in inflammatory bowel diseasePublication . Dias, A.; Correia, A.; Pereira, M.; Almeida, C.; Alves, I.; Pinto, V.; Catarino, T.; Mendes, N.; Leander, M.; Oliva-Teles, M.; Maia, L.; Delerue-Matos, C.; Taniguchi, N.i; Lima, Margarida; Pedroto, I.; Marcos-Pinto, Ricardo; Lago, P.; Reis, C.; Vilanova, M.; Pinho, S.Mucosal T lymphocytes from patients with ulcerative colitis (UC) were previously shown to display a deficiency in branched N-glycosylation associated with disease severity. However, whether this glycosylation pathway shapes the course of the T cell response constituting a targeted-specific mechanism in UC remains largely unknown. In this study, we demonstrated that metabolic supplementation of ex vivo mucosal T cells from patients with active UC with N-acetylglucosamine (GlcNAc) resulted in enhancement of branched N-glycosylation in the T cell receptor (TCR), leading to suppression of T cell growth, inhibition of the T helper 1 (Th1)/Th17 immune response, and controlled T cell activity. We further demonstrated that mouse models displaying a deficiency in the branched N-glycosylation pathway (MGAT5-/-, MGAT5+/-) exhibited increased susceptibility to severe forms of colitis and early-onset disease. Importantly, the treatment of these mice with GlcNAc reduced disease severity and suppressed disease progression due to a controlled T cell-mediated immune response at the intestinal mucosa. In conclusion, our human ex vivo and preclinical results demonstrate the targeted-specific immunomodulatory properties of this simple glycan, proposing a therapeutic approach for patients with UC.
- Recetores de citoxicidade natural nas células natural killer do sangue periféricoPublication . Santos, M.; Santos, A.; Oliveira, L.; Fonseca, S.; Rodrigues, J.; Gonçalves, M.; Queirós, M.; Leander, M.; Lau, C.; Teixeira, M.; Lima, M.
- Teste da eosina-5-maleimida (EMA), para o diagnóstico de esferocitose hereditária: experiência do Laboratório de Citometria de fluxo do Centro Hospitalar do PortoPublication . Queirós, M.; Antas, P.; Rocha, S.; Leander, M.; Freitas, I.; Cleto, E.; Barbot, J.; Rodrigues, J.; Gonçalves, M.; Santos, M.; Santos, A.; Oliveira, L.; Fonseca, S.; Lau, C.; Teixeira, M.; Pinho, L.; Santos-Silva, A.; Lima, M.